NAD+
Nicotinamide adenine dinucleotide
A coenzyme central to cellular energy metabolism and DNA repair, included here because it appears in almost every longevity protocol and is often sold alongside peptides. It is a small molecule, not a peptide.
- Category
- Longevity
- Half-life
- Minutes in circulation
- Cycle length
- Ongoing, or repeated IV courses
- Level
- intermediate
Overview
NAD+ is a coenzyme found in every living cell, essential for converting nutrients into energy and for activating the sirtuin family of proteins involved in DNA repair and cellular stress responses. Levels decline substantially with age in humans and animals. It is included in this library because it is a fixture of longevity protocols and is frequently purchased alongside peptides, though it is mechanistically and chemically a different class of substance.
How it works
NAD+ is a substrate for two key enzyme families: sirtuins, which deacetylate proteins involved in DNA repair and mitochondrial function, and PARPs, which are central to DNA damage repair. As NAD+ availability falls with age, both systems become less effective. Supplementing the precursor pool — via NR or NMN orally, or NAD+ intravenously — is the strategy, though how much reaches intracellular compartments is the contentious part.
Reported benefits
- Substrate for sirtuin and PARP enzyme families
- Central to mitochondrial energy production
- Reported improvements in fatigue and mental clarity
- Restoration of declining age-related levels in animal models
Reported benefits describe what the published literature and user reports suggest — not a promise of outcome for any individual.
Dosing reference
Oral precursors (NR or NMN) are described at 250–1000 mg daily. Intravenous NAD+ protocols use 250–1000 mg infused slowly over several hours; faster infusion reliably causes nausea and chest tightness.
Intravenous NAD+ must be infused slowly — the reaction to rapid infusion is intense and well documented. Oral bioavailability of NAD+ itself is poor, which is why precursors rather than the coenzyme are used orally.
Community-reported: 250–1,000 mg by slow intravenous infusion in clinics, or 250–500 mg daily of NR/NMN orally over weeks to months. Fast infusions are widely reported to cause nausea, chest tightness and flushing, and low blood pressure is a known risk of rapid administration.
These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.
Where the reported amounts come from
Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.
The research picture
Animal research consistently shows that raising NAD+ improves metabolic and mitochondrial markers and extends healthspan in mice. Human trials of oral precursors show reliable increases in blood NAD+ levels, but improvements in clinical outcomes remain far less clear — some trials show modest benefits in muscle function or insulin sensitivity, others show none. The mechanism is compelling and the human outcome data is genuinely mixed.
Preclinical & non-clinical data
NAD+ is a coenzyme, not a peptide: central to redox metabolism and the substrate for sirtuins, PARPs and CD38, with levels that decline with age in animal and human studies. Precursor supplementation reliably raises measured NAD+; the clinical consequence of that rise remains unproven.
Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.
What users report
Two separate reporting cultures. Clinic-infusion accounts describe sharper energy and mental clarity in the days after a session, along with a striking consensus that the infusion itself is unpleasant — chest tightness, flushing and nausea that people describe as the price of the effect. Oral precursor users report subtler changes in sleep and recovery over weeks, and a large group reporting nothing noticeable at all. Almost nobody in either group has measured NAD+ levels or compared against a placebo, which is the main limit of the whole body of reports.
Where these reports come from
These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.
Possible side effects
- Nausea, especially with rapid IV infusion
- Chest tightness or flushing with rapid infusion
- Headache
- Insomnia if dosed late in the day
- Fatigue reported with high-dose oral precursors
Safety notes
Safety data for long-term high-dose precursor use is limited. There is a theoretical concern that raising NAD+ availability could support proliferative processes, and PARP activation is relevant in some cancer contexts. Intravenous NAD+ should only be administered with clinical supervision given the reaction profile.
Stacking
Commonly combined with resveratrol or other sirtuin activators, and with Epithalon in longevity stacks. Oral precursors are frequently taken alongside NMN or NR rather than together in high doses.
Related compounds
Ipamorelin
NNC 26-0161
Longevity
A selective growth-hormone secretagogue with a clean profile.
Elamipretide (SS-31)
SS-31 — mitochondria-targeted tetrapeptide
Longevity
Elegant mitochondrial biology, repeatedly disappointing trial endpoints.
Humanin
24-amino-acid mitochondrial-derived peptide; HNG is a synthetic analogue
Longevity
The mitochondrial peptide that protects cells in the dish — and is sold well beyond its evidence.